flomoxef
Trade name: Flumarin
Small moleculeexperimental
Flomoxef is an oxacephem antibiotic that was developed by Shionogi. — Wikipedia
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Dec 1, 2015 (NCT02302092)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 3 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Penicillin-binding protein 1INHIBITOR
pbp1 inhibitor
- Bacterial penicillin-binding proteinINHIBITOR
Bacterial penicillin-binding protein inhibitor
- D-alanyl-D-alanine carboxypeptidase DacB (dacB) ↗
- Peptidoglycan D,D-transpeptidase FtsI (ftsI) ↗
- Penicillin-binding protein 1A (mrcA) ↗
- Penicillin-binding protein 1B (mrcB) ↗
- D-alanyl-D-alanine carboxypeptidase DacA (dacA) ↗
- Peptidoglycan D,D-transpeptidase MrdA (mrdA) ↗
- D-alanyl-D-alanine carboxypeptidase DacC (dacC) ↗
Chemistry & pharmacology
Loading structure…
SMILES
CO[C@@]1(NC(=O)CSC(F)F)C(=O)N2C(C(=O)O)=C(CSc3nnnn3CCO)CO[C@@H]21- Mol. weight
- 496.47 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaFlomoxef ↗
- ChEMBLCHEMBL15413 ↗
Also known as
- flomoxef
- flomoxef
- flomoxef
- flomoxef
- flomoxef
- flomoxef
- flomoxef
- flomoxef
- flomoxef sodium
- flomoxef sodium
- oxacephem 6315-s
- s 6315
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02302092 | Phase 3 | Dec 1, 2015 | Takeda |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Takeda | For profit | 1 | 1 | 1 | 2015 |
1 organizations
Page 1 / 1